Has Anita Mazloom, MD received payments from drug or device companies?

Yes. Drug and device makers reported $453,677 in general payments to Anita Mazloom, MD across 412 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anita Mazloom, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anita Mazloom, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anita Mazloom, MD

Hematology & Oncology · Mobile, ALNPI 1033607858

Payments from drug & device makers

$453,677in general payments, 2019–2025

Across 412 payments — averaging $1101.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$378K
Eli Lilly$57K
Sanofi$7K
AstraZeneca$2K
Pfizer$2K
Adaptive Biotechnologies Corporation$1K
plus $7K from 51 others

What the payments were for

Consulting fees$9,40048%
Speaking & faculty fees$1101%
Travel & lodging$1,6258%
Food & beverage$8,15641%
Education$3862%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	30	$377,508
Eli Lilly	2	$57,172
Sanofi	20	$6,545
AstraZeneca	9	$2,493
Pfizer	12	$1,850
Adaptive Biotechnologies Corporation	14	$1,456
Bristol Myers Squibb	36	$842
Novartis	44	$833
Eisai Inc.	32	$540
Merck	19	$420
Johnson & Johnson	18	$337
Regeneron Healthcare Solutions, Inc.	14	$308
Lilly USA, LLC	12	$303
Seagen Inc.	7	$288
Amgen	15	$237
Daiichi Sankyo Inc.	12	$235
Incyte Corporation	11	$235
Ipsen Biopharmaceuticals, Inc	4	$171
Takeda Pharmaceuticals U.S.A., Inc.	8	$166
AbbVie	6	$151
Taiho Oncology, Inc.	7	$125
Genmab U.S., Inc.	6	$104
Beigene USA, Inc.	6	$103
Sobi, Inc	5	$93
GSK	5	$86
Genentech USA, Inc.	5	$82
Array Biopharma Inc	4	$78
EMD Serono, Inc.	4	$74
Pharmaessentia USA Corporation	3	$73
Bayer	3	$56
Servier Pharmaceuticals LLC	3	$53
Tersera Therapeutics LLC	2	$52
Stemline Therapeutics Inc.	3	$51
Exelixis Inc.	2	$44
Immunocore Limited	2	$44
Blueprint Medicines Corporation	2	$43
ADC Therapeutics America, Inc.	2	$42
Pharmacosmos Therapeutics Inc.	2	$33
Immunogen, Inc.	2	$32
Karyopharm Therapeutics Inc.	2	$29
Novocure Inc.	1	$24
Boehringer Ingelheim	1	$22
Rigel Pharmaceuticals, Inc.	1	$22
CTI Biopharma Corp.	1	$21
Dendreon Pharmaceuticals LLC	1	$20
Gilead	1	$17
Corcept Therapeutics	1	$17
Astellas Pharma US Inc	1	$16
Deciphera Pharmaceuticals Inc.	1	$16
Beone Medicines USA, Inc.	1	$15
Morphosys, US Inc.	1	$15
Puma Biotechnology, Inc.	1	$15
Apellis Pharmaceuticals, Inc.	1	$15
Myriad Genetic Laboratories, Inc.	1	$14
Cumberland Pharmaceuticals, Inc.	1	$14
Acrotech Biopharma Inc.	1	$14
Veracyte, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CALQUENCE$2,345
ADCETRIS$1,625
clonoSEQ$882
SARCLISA$162
TAZVERIK$142
OPDIVO$115
KEYTRUDA$105
VERZENIO$101
JAYPIRCA$101

How this compares

$453,677 in reported general payments places this provider in the 80th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$4,449

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Mobile

Michael MeshadMobile$5.3M
Jose Galeas SorianoMobile$536K
Sherri ArledgeMobile$358K
Brian HellerMobile$213K
Thaddeus BeekerMobile$195K
Prajwol PathakMobile$158K
Ahmed AbdallaMobile$141K
Luciano CostaBirmingham$32.8M
Amitkumar MehtaBirmingham$18.6M
Erica Stringer-ReasorBirmingham$18.1M

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →